A Phase 2 interventional study of GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea and GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea in Polycythemia Vera, sponsored by Italfarmaco. Completed at 22 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-31.
Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Polycythemia Vera with a site in Italy — 8 open to participants now, 15 under way, 3 of them phase 3. Polycythemia Vera · Italy.
Among the 44 studies in Polycythemia Vera with a site in Italy, this one is the 27th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2009, is one of 11 in phase 2, and was the 10th registered.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →8 of the 44 studies in Polycythemia Vera with a site in Italy are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Prelude Therapeutics Incorporated · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Sites in Italy, United States, Germany and 2 more countries
Ages 18–100
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy
Ages 16+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 11 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Median enrollment 127 across the 31 interventional studies, 429 across the 13 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 44 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 5 studies filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
5 of the studies in Polycythemia Vera with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07203768FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSA ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes | 2026-12-31 |
| NCT05548062Novartis PharmaceuticalsStudy to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | 2027-08-31 |
| NCT07518940Carmen FavaENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Polycythemia Vera with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy.
The secondary objectives of this study were:
This is a multicentre, randomized, open-label, phase II study testing GIVINOSTAT (ITF2357) in combination with hydroxyurea in a population of patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.
Recruited patients will be randomly assigned to one of the following treatment groups:
The two groups will be balanced for number and for Centre in order to provide valuable information on both treatment regimens.
In both groups assigned doses shall remain stable until week 12, which is when the primary endpoint is assessed, unless specific tolerability issues arise which impose dose reduction.
After the primary endpoint assessment at week 12, one of the following treatment schedules will be chosen case by case on the basis of the achieved clinical response and continued for up to 12 further weeks:
The study will recruit subjects of both genders with an established diagnosis of JAK2V617F positive Polycythemia Vera according to the revised WHO criteria, in need of cytoreductive therapy, non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
cardiovascular disease including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea
50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
Drug page: Givinostat
50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
Also known as: GIVINOSTAT (ITF2357), ONCOCARBIDE (HYDROXYUREA)
Drug page: Givinostat
50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
Also known as: GIVINOSTAT (ITF2357), ONCOCARBIDE (HYDROXYUREA)
Percentage of Patients With Overall Haematological Response at Week 12.
The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) \< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.
Time frame: At week 12 of treatment
Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12.
Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12). * Complete response: 1. HCT\< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); * Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; * No response: any response that did not satisfy the criteria set for partial response.
Time frame: At week 24 of treatment
Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR
To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs).
Time frame: At weeks 12, 24, at "drop out visit" and at "End of Study" (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24.
Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints
JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks). Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid)
Time frame: Baseline, at weeks 12 and 24
| Milestone | GIVINOSTAT +Maximum Tolerated Dose (MTD) of Hydroxyurea (HU)_1 | GIVINOSTAT +Maximum Tolerated Dose (MTD) of Hydroxyurea (HU)_2 |
|---|---|---|
| Started | 23 | 22 |
| Completed | 22 | 22 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) \< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.
| percentage of particpants | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 |
|---|---|---|
| Responder | 54.5 (33.7 to 75.4) | 50.0 (29.1 to 70.9) |
| Non responder | 45.5 (24.6 to 66.3) | 50.0 (29.1 to 70.9) |
Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12). * Complete response: 1. HCT\< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); * Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; * No response: any response that did not satisfy the criteria set for partial response.
| percentage of participants | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 |
|---|---|---|
| Responder | 63.6 (43.5 to 83.7) | 40.9 (20.4 to 61.5) |
| Non responder | 36.4 (16.3 to 56.5) | 59.1 (38.5 to 79.6) |
To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs).
| percent change | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 |
|---|---|---|
| Week 12 | -2.6 ± 8.2 | 0.00 ± 6.0 |
| Week 24 | -3.8 ± 11.5 | 4.6 ± 5.7 |
| Drop-out | -4.0 ± 0.00 | -9.5 ± 20.5 |
| EOS | -3.8 ± 11.1 | 3.0 ± 8.6 |
JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks). Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid)
| percentage of participants | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 |
|---|---|---|
| Baseline - heterozygous | 27.3 | 22.7 |
| Baseline - homozygous | 72.7 | 72.7 |
| Baseline - not done | 0 | 4.5 |
| week 12 - heterozygous | 25.0 | 31.6 |
| week 12 - homozygous | 70.0 | 63.2 |
| week 12 - not done | 5.0 | 5.3 |
| week 24 - heterozygous | 22.2 | 11.1 |
| week 24 - homozygous | 72.2 | 77.8 |
| week 24 - not done | 5.6 | 11.1 |
Collected over Adverse events (AEs) were recorded at weeks 1 ,3, 6, 9, 12, 16, 20 or end of treatment visit (week 24 or 7 days after last drug intake). Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GIVINOSTAT + MTD Hydroxyurea_1 | 0/22 (0%) | 2/22 (9.1%) | 21/22 (95.5%) |
| GIVINOSTAT + MTD Hydroxyurea_2 | 0/22 (0%) | 1/22 (4.5%) | 21/22 (95.5%) |
| Event | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 |
|---|---|---|
| AppendicectomySurgical and medical procedures | 1/22 | 0/22 |
| EmbolismRespiratory, thoracic and mediastinal disorders | 1/22 | 0/22 |
| Pregnancy of partnerSocial circumstances | 0/22 | 1/22 |
| Event | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 10/22 | 7/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/22 | 7/22 |
| Blood creatinine increasedInvestigations | 3/22 | 2/22 |
| Abdominal painGastrointestinal disorders | 3/22 | 1/22 |
| Abdominal pain upperGastrointestinal disorders | 2/22 | 3/22 |
| NauseaGastrointestinal disorders | 3/22 | 0/22 |
| InfluenzaInfections and infestations | 3/22 | 1/22 |
| HypertensionVascular disorders | 0/22 | 2/22 |
| AstheniaGeneral disorders | 2/22 | 2/22 |
| FatigueGeneral disorders | 2/22 | 1/22 |
Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.
| Age, Categorical(Participants) | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 11 | 21 |
| >=65 years | 13 | 11 | 24 |
| Sex: Female, Male(Participants) | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 | Total |
|---|---|---|---|
| Female | 9 | 7 | 16 |
| Male | 14 | 15 | 29 |
| Region of Enrollment(participants) | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 | Total |
|---|---|---|---|
| Italy | 23 | 22 | 45 |
The record gives a start of Jun 2009, a primary completion of Jul 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 8 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat